GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Singular Genomics Systems Inc (NAS:OMIC) » Definitions » Interest Coverage

Singular Genomics Systems (Singular Genomics Systems) Interest Coverage : 0 (At Loss) (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Singular Genomics Systems Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Singular Genomics Systems's Operating Income for the three months ended in Mar. 2024 was $-26.85 Mil. Singular Genomics Systems's Interest Expense for the three months ended in Mar. 2024 was $-0.28 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Singular Genomics Systems's Interest Coverage or its related term are showing as below:


OMIC's Interest Coverage is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 18.02
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Singular Genomics Systems Interest Coverage Historical Data

The historical data trend for Singular Genomics Systems's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Singular Genomics Systems Interest Coverage Chart

Singular Genomics Systems Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
- - - - -

Singular Genomics Systems Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Singular Genomics Systems's Interest Coverage

For the Medical Instruments & Supplies subindustry, Singular Genomics Systems's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Singular Genomics Systems's Interest Coverage Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Singular Genomics Systems's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Singular Genomics Systems's Interest Coverage falls into.



Singular Genomics Systems Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Singular Genomics Systems's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Singular Genomics Systems's Interest Expense was $-1.10 Mil. Its Operating Income was $-102.80 Mil. And its Long-Term Debt & Capital Lease Obligation was $67.52 Mil.

Singular Genomics Systems did not have earnings to cover the interest expense.

Singular Genomics Systems's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, Singular Genomics Systems's Interest Expense was $-0.28 Mil. Its Operating Income was $-26.85 Mil. And its Long-Term Debt & Capital Lease Obligation was $65.72 Mil.

Singular Genomics Systems did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Singular Genomics Systems  (NAS:OMIC) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Singular Genomics Systems Interest Coverage Related Terms

Thank you for viewing the detailed overview of Singular Genomics Systems's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Singular Genomics Systems (Singular Genomics Systems) Business Description

Traded in Other Exchanges
N/A
Address
3010 Science Park Road, San Diego, CA, USA, 92121
Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.
Executives
Andrew Spaventa director, 10 percent owner, officer: Chief Executive Officer 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Eli N. Glezer officer: Chief Scientific Officer 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Jyotsna Ghai officer: Chief Operating Officer 3010 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Kim P. Kamdar director C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Marcia Eisenberg director C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Sam Ropp officer: Chief Commercial Officer 3010 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Michael J Pellini director 222 DUTTON MILL RD, WILLISTOWN PA 19380
Elaine R Mardis director 301 MERRITT 7, NORWALK CT 06851
James E Flynn 10 percent owner, other: *Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
David Daly officer: President and Chief Operating 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Vincent Brancaccio officer: Vice President, HR 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Dalen Meeter officer: Vice President, Finance 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Daralyn Durie officer: General Counsel 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Jorge Velarde officer: Senior Vice President 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
David L Barker director 9885 TOWNE CENTRE DR, SAN DIEGO CA 92121